|
|
|
| Research progress in clinical treatment of advanced non-small cell lung cancer patients with human epidermal growth factor receptor 2 changes |
| ZHANG Mengke CAO Jingyan ZHOU Shuhan SUN Qingyu |
Ward Three, Department of Respiratory Medicine, Affiliated Cancer Hospital of Harbin Medical University, Heilongjiang Province, Harbin 150000, China
|
|
|
|
Abstract Human epidermal growth factor receptor 2 is one of the driver genes for non-small cell lung cancer and is associated with poor prognosis. Among tyrosine kinase inhibitors, Poziotinib and Pyrotinib have good efficacy; Mobotinib has a high affinity for exon 20 insertion mutations. Treatment with Trastuzumab can be used in patients with first-line progression. The efficacy of antibody drug conjugates is the most encouraging, and Trastuzumab-Deruxtecan has obtained unprecedented efficacy data. Although immune checkpoint inhibitors are not recommended, combination immunotherapy may bring new life to patients.
|
|
|
|
|
|
[1] Wu HX，Zhuo KQ，Wang K. Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer：A systematic review and meta-analysis [J]. Br J Clin Pharmacol，2022，88（5）：2019-2034.
[2] Mazieres J，Barlesi F，Filleron T，et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2- targeted drugs：results from the European EUHER2 cohort [J]. Ann Oncol，2016，27（2）：281-286.
[3] Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma [J]. Nature，2014， 511 （7511）：543-550.
[4] Diao WY，Ding CL，Yuan BY，et al. Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer [J]. Int J Gen Med，2021，14：9153-9161.
[5] Eng J，Hsu M，Chaft JE，et al. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers [J]. Lung Cancer，2016，99：53-56.
[6] Mazières J，Peters S，Lepage B，et al. Lung cancer that harbors an HER2 mutation：epidemiologic characteristics and therapeutic perspectives [J]. J Clin Oncol，2013，31（16）：1997-2003.
[7] Fan Y，Chen J，Zhou C，et al. Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations，previously treated with chemotherapy：A phase Ⅱ trial [J]. Lung Cancer，2020，147：209-213.
[8] Dziadziuszko R，Smit EF，Dafni U，et al. Afatinib in NSCLC With HER2 Mutations：Results of the Prospective，Open-Label Phase Ⅱ NICHE Trial of European Thoracic Oncology Platform （ETOP） [J]. J Thorac Oncol，2019，14（6）：1086- 1094.
[9] Fang W，Zhao S，Liang Y，et al. Mutation Variants and Co- Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma [J]. Oncologist，2020， 25（3）：e545-e554.
[10] Lai WV，Lebas L，Barnes TA，et al. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers：a retrospective international multicentre study [J]. Eur J Cancer，2019，109：28-35.
[11] Li BT，Lee A，O’Toole S，et al. HER2 insertion YVMA mutant lung cancer：Long natural history and response to afatinib [J]. Lung Cancer，2015，90（3）：617-619.
[12] Yamamoto H，Toyooka S，Ninomiya T，et al. Therapeutic Potential of Afatinib for Cancers with ERBB2 （HER2） Transmembrane Domain Mutations G660D and V659E [J]. Oncologist，2018，23（2）：150-154.
[13] Fisher B，Brown A，Mamounas E，et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer：findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J]. J Clin Oncol，1997，15（7）：2483-2493.
[14] Wang J，Wen Y，Ding G，et al. Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation [J]. Cancer Biol Ther，2018，19（6）：450-453.
[15] Kris MG，Camidge DR，Giaccone G，et al. Targeting HER2 aberrations as actionable drivers in lung cancers：phase Ⅱ trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors [J]. Ann Oncol，2015，26（7）：1421-1427.
[16] Hyman D，Piha-Paul S，Won H，et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers [J]. Nature，2018，554（7691）：189-194.
[17] Robichaux JP，Elamin YY，Tan Z，et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer [J]. Nat Med，2018，24（5）：638-646.
[18] Oh I J，Hur JY，Park CK，et al. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma [J]. Clin Lung Cancer，2018，19（5）：e775-e781.
[19] Robichaux J，Elamin Y，Vijayan R，et al. Pan-Cancer Land- scape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T- DM1 Activity [J]. Cancer cell，2019，36（4）：444-457.e447.
[20] Le X，Cornelissen R，Garassino M，et al. Poziotinib in Non- Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies：ZENITH20-2 Trial [J]. J Clin Oncol，2022，40（7）：710-718.
[21] Elamin YY，Robichaux JP，Carter BW，et al. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer：Results From a Phase Ⅱ Trial [J]. J Clin Oncol， 2022，40（7）：702-709.
[22] Wang Y，Jiang T，Qin Z，et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib [J]. Ann Oncol，2019，30（3）：447-455.
[23] Shan J，Ruan J，Tan Y，et al. Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions：A Case Report [J]. Onco Targets Ther，2020，13：9849-9856.
[24] Zhou C，Li X，Wang Q，et al. Pyrotinib in HER2-Mutant Ad-vanced Lung Adenocarcinoma After Platinum-Based Chemotherapy：A Multicenter，Open-Label，Single-Arm，Ph ase Ⅱ Study [J]. J Clin Oncol，2020，38（24）：2753-2761.
[25] Jia Z，Xing J，Li J，et al. HER2 transmembrane domain mutation：comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma [J]. Transl Lung Cancer Res，2021，10（3）：1383-1396.
[26] Ni J， Si XY， Zhang L. Non-small-cell lung cancer with ER- BB2 mutation in non-tyrosine kinase domain benefits from pyrotinib：A case report [J]. Thorac Cancer，2021，12（8）：1244-1247.
[27] Song Z，Lv D，Chen SQ，et al. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer：A Prospective，Multicenter，Single-Arm Trial [J]. Clin Cancer Res，2022，28（3）：461-467.
[28] Uy NF，Merkhofer CM，Baik CS. HER2 in Non-Small Cell Lung Cancer：A Review of Emerging Therapies [J]. Cancers（Basel），2022，14（17）：4155.
[29] Riely GJ，Neal JW，Camidge DR，et al. Activity and Safety of Mobocertinib （TAK-788） in Previously Treated Non- Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase Ⅰ/Ⅱ Trial [J]. Cancer Discov，2021，11（7）：1688-1699.
[30] Serra V，Vivancos A，Puente XS，et al. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation [J]. Cancer Discov，2013，3（11）：1238-1244.
[31] Lopez-Chavez A，Thomas A，Rajan A，et al. Molecular pr- ofiling and targeted therapy for advanced thoracic malignancies：a biomarker-derived，multiarm，multihistology pha- se Ⅱbasket trial [J]. J Clin Oncol，2015，33（9）：1000-1007.
[32] Estrada-Bernal A，Le AT，Doak AE，et al. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes [J]. Clin Cancer Res，2021，27（5）：1463-1475.
[33] Koga T，Suda K，Nishino M，et al. Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer：an in vitro study [J]. Transl Lung Cancer Res，2021， 10（8）：3659-3670.
[34] Mazieres J，Lafitte C，Ricordel C，et al. Combination of Trastuzumab，Pertuzumab，and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations：Results From the IFCT-1703 R2D2 Trial [J]. J Clin Oncol，2022，40（7）：719-728.
[35] Hainsworth JD，Meric-Bernstam F，Swanton C，et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles：Results From MyPathway，an Open-Label，Phase Ⅱa Multiple Basket Study [J]. J Clin Oncol，2018， 36（6）：536-542.
[36] Vathiotis IA，Charpidou A，Gavrielatou N，et al. HER2 Abe- rrations in Non-Small Cell Lung Cancer：From Pathophysiology to Targeted Therapy [J]. Pharmaceuticals （Basel），2021，14（12）：1300.
[37] Hotta K，Aoe K，Kozuki T，et al. A Phase Ⅱ Study of Tras- tuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer [J]. J Thorac Oncol，2018，13（2）：273-279.
[38] Li BT，Shen R，Buonocore D，et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers：Results From a Phase Ⅱ Basket Trial [J]. J Clin Oncol，2018， 36（24）：2532-2537.
[39] Iwama E，Zenke Y，Sugawara S，et al. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations [J]. Eur J Cancer，2022，162：99-106.
[40] Li BT，Michelini F，Misale S，et al. HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers [J]. Cancer Discov，2020，10（5）：674-687.
[41] Peters S，Stahel R，Bubendorf L，et al. Trastuzumab Emtansine （T-DM1） in Patients with Previously Treated HER2- Overexpressing Metastatic Non-Small Cell Lung Cancer：Efficacy，Safety，and Biomarkers [J]. Clin Cancer Res，2019， 25（1）：64-72.
[42] Doi T，Shitara K，Naito Y，et al. Safety，pharmacokinetics，and antitumour activity of trastuzumab deruxtecan （DS- 8201），a HER2-targeting antibody-drug conjugate，in patients with advanced breast and gastric or gastro-oesoph- ageal tumours：a phase 1 dose-escalation study [J]. Lancet Oncol，2017，18（11）：1512-1522.
[43] Trastuzumab Deruxtecan DESTINY for Some Cancers [J]. Cancer discovery，2020，10（7）：898.
[44] Desai A，Abdayem P，Adjei AA，et al. Antibody-drug conjugates：A promising novel therapeutic approach in lung cancer [J]. Lung Cancer，2022，163：96-106.
[45] Kato Y，Kato Y，Minegishi Y，et al. Efficacy with Trastu- zumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status：A Case Report [J]. Onco Targets Ther，2021，14：5315-5319.
[46] Li BT，Smit EF，Goto Y，et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer [J]. N Engl J Med，2022，386（3）：241-251.
[47] Horvath L，Pircher A. ASCO 2020 non-small lung cancer （NSCLC） personal highlights [J]. Memo，2021，14（1）：66- 69.
[48] Tsurutani J，Iwata H，Krop I，et al. Targeting HER2 with Trastuzumab Deruxtecan：A Dose-Expansion，PhaseⅠ Study in Multiple Advanced Solid Tumors [J]. Cancer Discov，2020， 10（5）：688-701.
[49] Shi F，Liu Y，Zhou X，et al. Disitamab vedotin：a novel antibody-drug conjugates for cancer therapy [J]. Drug Deliv，2022，29（1）：1335-1344.
[50] Ren S，Wang J，Ying J，et al. Consensus for HER2 alterations testing in non-small-cell lung cancer [J]. ESMO Open，2022，7（1）：100395.
[51] 李腾，李峻岭.免疫检查点抑制剂治疗少见突变非小细胞肺癌疗效的研究进展[J].中国肺癌杂志，2021，24（1）：19-24.
[52] Mazieres J，Drilon A，Lusque A，et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations：results from the Immunotarget registry [J]. Ann Oncol，2019，30（8）：1321-1328.
[53] Guisier F，Dubos-Arvis C，Vinas F，et al. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF，HER2，or MET Mutations or RET Translocation：GFPC 01-2018 [J]. J Thorac Oncol，2020，15（4）：628-636.
[54] Yang G，Yang Y，Liu R，et al. First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC：a retrospective real-world POLISH study [J]. Ther Adv Med Oncol，2022，14：17588359221082339.
[55] D’Amico L，Menzel U，Prummer M，et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer [J]. J Immunother Cancer，2019，7（1）：16. |
|
|
|
